Vertex Pharma stock gains 3 percent ahead of the open
Published on 09/23/2026 at 02:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharma stock closed at USD 524.05 on the Nasdaq on September 22, 2026, up 3 percent. The Nasdaq Composite rose 0.5 percent to 27,244.28 in the same session, giving Vertex a gain of 2.5 percentage points over the reference index.
September 22, 2026 in numbers
Vertex Pharmaceuticals Incorporated (ISIN US92532F1003, Nasdaq: VRTX) traded at USD 524.05 after the company announced positive AMPLIFIED study results for inaxaplin. As Business Wire reported on September 22, 2026, the study showed a 42.7 percent reduction in a kidney-disease proteinuria measure in one patient group.
The company also completed enrollment in the Phase 2/3 AMPLITUDE trial, with interim data expected in early 2027. Vertex gained 3 percent while the Nasdaq Composite added 0.5 percent on September 22, 2026.
Today after the trial update
The AMPLIFIED results remain the key company-specific development for Vertex on September 23, 2026. As Investing.com reported on September 22, 2026, BMO Capital reiterated an Outperform rating and a USD 600 price target after the trial data.
